The impact of the common alleles at structural loci coding for apolipoproteins (apos) A-IV, E, and H on 12 quantitative risk factors for cardiovascular disease (apos A-I, A-II, B, C-II, C-III, and E; total cholesterol; triglycerides; high density lipoprotein cholesterol; systolic blood pressure; diastolic blood pressure; and red blood cell sodium-lithium countertransport) was estimated in 453 unrelated individuals (227 men and 226 women) aged 26-63 years from the Rochester Family Heart Study, who were not using medications affecting lipid levels or blood pressure. Each risk factor was adjusted for concomitants (assay date, age, age squared, height, weight, and smoking status) before the genotypic effects on mean levels and variances were estimated. Allele frequencies were the same in men and women and were similar to those observed in other studies of US Caucasians. There were very different gender-specific estimates of the relative contribution of concomitants, measured genetic effects, and residual unexplained effects to the interindividual variation of particular traits. Allelic variation in apo E had effects on the greatest number of traits, namely apo E, apo B, apo C-II, and total cholesterol. An effect on triglycerides was dependent on the inclusion of hypertriglyceridemic subjects. Allelic effects of apo A-IV and apo H were much less than those estimated for the apo E polymorphism. A possible role for apo H in high density lipoprotein metabolism is suggested. This study indicates that variation in many genes may influence variation in a particular trait and that a particular gene may have pleiotropic effects on several traits. (Arteriosclerosis and Thrombosis 1991;ll:1330-1348)
A polipoproteins are the protein components of / \ the lipoproteins that play a central function .Z \ . in the metabolism of lipids. Variations in apolipoprotein levels have been associated with the levels of plasma lipids and the risk of developing atherosclerotic disease.
-
12 Recent reviews of the structure and function of individual apolipoproteins document their specific roles as ligands, cofactors, and structural components of lipoprotein particles. 13 " 18 As is the case for lipid levels, both genetic and environmental factors are involved in the determination of interindividual variation in plasma levels of the apolipoproteins. 19 - 21 A fraction of this variability may be associated with structural variation in the gene coding for the protein 22 or variability in regulatory sequences. 23 Other genes, however, may also influence the levels of the apolipoprotein and thus influence plasma lipoprotein and lipid levels. Such epistatic effects of unlinked genes occur for the lipoprotein lipase gene 24 in the mouse and the apolipoprotein (apo) E gene 25 in humans. In addition to plasma lipids and apolipoproteins, other major risk factors for atherosclerotic disease include blood pressure, smoking, and obesity. As is true for lipids, many intermediate biochemical and physiological traits have been identified that link variations in cause with variations in risk of disease. For blood pressure, one such intermediate trait of great interest has been red blood cell (RBC) sodiumlithium (Na-Li) countertransport (CNT). 26 - 29 Because this membrane trait has also been associated with plasma lipid levels, 30 variability of the intermediate quantitative biologic risk factor traits for cardiovascular disease in the population at large. 33 We are asking, for each risk factor trait, how many segregating genes are involved in determining the genetic component of variation, how many alleles are at each gene, and what is the impact of each allele on an individual's level and the interindividual variance in the population at large. We consider here the structural genes coding for apos E, A-IV, and H, which are polymorphic at the protein level. 34 " 37 These protein polymorphisms have been selected because they are candidates for influencing the interindividual variation in lipid and lipoprotein traits known to impact on coronary artery disease (CAD) risk.
Apo E is one of the most extensively studied polymorphic gene products involved in lipid metabolism. 16 A multitude of functions for this 299-residue molecule have been described. 18 It is involved in catabolism of triglyceride-rich lipoprotein particles secreted by the intestine. It is a structural component of several lipoprotein particles and acts as a ligand for tissue-specific receptors. Apo E is also involved in immunoregulation and modulation of cell growth and differentiation. 18 The precise functional role of apo A-IV, a 376-amino acid polypeptide, in lipid metabolism is not clear. It is found in triglyceride-rich lipoproteins secreted by the intestine, in high density lipoprotein (HDL) particles, and also in a free form unassociated with major lipoproteins. 38 It is involved in the activation of lecithin: cholesterol acyltransferase. 39 Apo A-IV is hypothesized to participate in reverse cholesterol transport in a manner similar to that of apo A-I, 15 which it closely resembles in structure. 40 Apo H, also known as /3-2 glycoprotein I, has only recently been assigned to the class of apolipoproteins. Very little is known about its function in lipid metabolism. Apo H is a 326-amino acid glycoprotein first described in 1961 41 that has been well characterized biochemically. 42 " 44 It is associated with chylomicrons and HDL particles. 4546 It may be involved in triglyceride metabolism 4748 and is an activator of lipoprotein lipase. 49 The mean plasma level of apo H is about 20 mg/dl. 50 Persons with no detectable levels of apo H 51 -52 appear to be clinically normal. However, they do have low concentrations of HDLa, and HDL,. 52 Schousboe 53 suggests that persons with low or deficient apo H levels in plasma may be prone to developing coagulation defects.
Apo E and apo A-IV belong to the apolipoprotein multigene family. 1540 The gene coding for apo E is located on chromosome 19, and the gene coding for apo A-IV is located on the long arm of chromosome 11 in the cluster coding for apo A-I/C-III/A-IV. The gene coding for apo H is on chromosome 17 (R.E. Ferrell, personal communication). All three genes are polymorphic, that is, each has at least two alleles with a relative frequency greater than 0.02. For apo E, there are three common allelic forms of the structural gene, denoted as e 2 , e 3 , and e 4 , that code for differences at amino acid residues 112 and 158. These distinguish the three isoforms, E2, E3, and E4, of apo E, which are present in all but one of the populations studied 16 with a relative frequency greater than 0.02. In Caucasian populations two common allelic forms and other rarer alleles of the apo A-IV polymorphism have been identified. 36 -54 " 58 The common alleles are designated as A-IV*1 and A-IV*2. Some other rare alleles occur in non-Caucasian populations. 58 
"
60 The structural locus for apo H has three common alleles in the US population, 37 -61 designated H*l, H*2, and H*3. A fourth rare allele has been reported in blacks. 37 In this article we assess causes of interindividual variation in six plasma apolipoproteins (A-I, A-II, B, C-II, C-III, and E), three plasma lipids (total cholesterol, triglycerides, and HDL cholesterol), two blood pressure variables (systolic and diastolic blood pressures), and RBC Na-Li CNT. We first consider the contribution of concomitant variation in assay date, age, height, weight, and smoking status to phenotypic variation in each of these quantitative risk factor traits. Then we estimate the impact of variation in common alleles at structural loci coding for apos E, A-IV, and H. The magnitude of the contribution of concomitants was trait specific and differed between genders in most cases. Each of the three polymorphisms has its own characteristic gender-specific profile of effects on the average levels and the population variance. Allelic variation in apo E has the greatest impact on plasma levels of cholesterol, triglycerides, and apos B, C-II, and E, while the greatest impact of apo H variation is on plasma levels of apo A-I. In contrast, genetic variation at the apo A-IV locus does not significantly influence interindividual variability of lipid or apolipoprotein levels but has a statistically significant effect on interindividual differences in levels of RBC Na-Li CNT.
Methods

Population Studied and Definition of Sample
Moll et al 21 and Turner et al 62 described the Rochester Family Heart Study (begun in January 1984) whose purpose was to identify and characterize the genetic factors involved in determining predisposition to hypertension and coronary heart disease in the population at large. Multigeneration pedigrees were ascertained without regard to health status through households with two or more children enrolled in the city's public and parochial primary and secondary schools. As of January 1988, 2,004 individuals (99.6% Caucasian) had completed a clinic visit, during which time a questionnaire (mailed in advance) on medical history was completed, a physical exam was performed, and a blood sample was drawn. Moll et al 21 described the clinic protocol. These 2,004 individuals for whom laboratory assays were performed were distributed among 283 pedigrees. Pedigree size ranged from one to 24 (average=6.64) . The study reported herein is based on data for 567 unrelated spouses from these pedigrees who were parents of the index school children. All subjects were measured for lipids, apolipoproteins, and blood pressure. This sample was reduced by removing individuals who were taking medications that might have affected lipid metabolism or blood pressure at the time the plasma was sampled. Men (31 of 279) taking one or more of such medications (diuretics, /3-blockers, Ca 2+ blockers, a-blockers, estrogen, progesterone, glucocorticoids, thyroid hormone, insulin, oral hypoglycemics, lipid-lowering drugs, and cisretinoid acid) were 3.5 years older (probability [/V]<0.01) and had significantly higher (i 3 r<0.05) average levels of RBC Na-Li CNT, systolic and diastolic blood pressures, total cholesterol, and triglycerides. Plasma levels of triglycerides, apo A-I, apo A-II, apo C-II, apo C-III, and RBC Na-Li CNT were significantly elevated in the sample of 41 (of 288) women taking such medications. In addition to these differences in mean levels, there was significantly greater interindividual variation in plasma apo E (/V<0.001) among persons taking medications compared with those not taking medications in both sexes.
After exclusion of the 31 men and 41 women described above, 495 individuals remained. Genotype was determined for apo E in 479 persons, for apo H in 480 persons, and for apo A-IV in 459 persons. Although several rare alleles have been detected in the total sample of 2,004 individuals, none occurred in the sample of unrelated individuals considered here. Genotype information was available for all three loci in 453 persons (227 men and 226 women), the final sample for the analysis presented here. Means and variances of this sample were compared with those of persons not genotyped for all three loci and not taking medications (n=42). Only apo A-I was elevated among men not completely genotyped (n=21) (iV<0.05). These men also displayed less phenotypic variability in triglycerides, HDL cholesterol, and apo A-II. Women who did not have complete genotypes (n=21) were less variable for systolic blood pressure than were fully genotyped women (Pr<0.05).
Measures at Clinic Visit
Height was measured in centimeters with a wall stadiometer, and weight was measured in kilograms on a beam balance after subjects had removed their shoes and outer clothing. Respondents were classified as never having been a smoker, former smoker, or current smoker. Blood pressure was measured with a random-zero sphygmomanometer (Hawksley & Sons, Ltd., West Sussex, England) after selection of a cuff size appropriate for the subject's arm. Pressure at the Korotkoff phase I sound was taken as systolic blood pressure, and pressure at the Korotkoff phase V sound was taken as diastolic blood pressure. Averages of three readings in the right arm at least 2 minutes apart were used as the systolic and diastolic blood pressure values in this study.
Laboratory Measures
Plasma cholesterol and triglyceride levels were measured by standard enzymatic methods 63 -65 with quality control plasma pools. Low density lipoprotein (LDL) and very low density lipoprotein (VLDL) particles were precipitated with polyethylene glycol 6000, and an aliquot of the supernatant was used for the determination of HDL cholesterol by an enzymatic method. This method gives values that are the same as those obtained with the Lipid Research Clinics heparin-manganese method and avoids problems with cloudy supernatants and the potential for interference with the enzymatic determination of cholesterol. 66 -69 Plasma levels of apos A-I, 70 A-II, 7 ' C-II, 72 C-III, 73 and E 74 were measured by radioimmunoassays (RIAs) developed at the Mayo Atherosclerosis Laboratory. Apo B was measured on total plasma by use of a monoclonal enzyme-linked immunosorbent assay (ELISA). The nonspecific binding, the slope of the logit-derived standard curve, and the values of one or more quality control plasmas (six replicates each) were monitored with each assay run. All iodine-125-labeled apolipoproteins were checked for trichloroacetic acid precipitability. Those with less than 85% precipitability of radioactive counts were discarded and not used in the assays. Purity of the isolated apolipoprotein standards was checked by amino acid analysis as well as by gel electrophoresis and reactivity with antibodies to other apolipoproteins. If any of the six replicate assays of a sample fell outside the normal range of variability for the assay, the sample was rerun. The normal range was considered to be two standard deviation units to either side of the mean of the six replicates; the standard deviation was computed from the variability among replicate assays within individuals over all individuals who were included in the run. (This algorithm normally flags between 8-12% of the samples for rerunning.) When the samples were rerun, the six replicates were run again, and the same criteria were applied. Using this system, we have eliminated technician bias in determining which samples needed to be rerun. 7475 To reduce day-to-day interassay variability, all assays were corrected on the basis of values for the quality control plasma that was included in each run. Interassay variability was monitored by running each sample at two dilutions, with three replicate assays of each dilution (total of six replicates) for the RIAs and at two dilutions with two replicates (total of four replicates) for the ELISA assays. All automatic syringes and the diluters were calibrated by weighing pipetted samples on a regular basis.
Genetic variation in the products of the apo E, A-IV, and H loci was determined by isoelectric focusing-immunoblotting of plasma samples, as described by Kamboh et al. 37 -5576 Levels of RBC Na-Li CNT were determined as the rate of sodium gradient-dependent lithium efflux from lithium-loaded RBCs by the method of Canessa and Tosteson, 77 as described previously in Turner et al. 27 
Statistical Methods
Statistical tests that gave /Y<0.05 were considered significant unless otherwise denoted. Analyses were performed separately for men and women whenever possible because there were substantial gender differences in the frequency distributions of the major risk factors (blood lipids, blood pressure, obesity, and smoking), 78 trends in these risk factors over time, 79 and rates of atherosclerotic disease. 80 Multiple regression was used to estimate the linear effects of concomitants for each gender separately. Genderspecific means were added to the residuals from the gender-specific regression analyses before performing an analysis of variance to test for differences among genotype means. Equality of genotype-specific variances was investigated, as heteroscedasticity can affect the validity of the F test of differences among genotype means. When heterogeneity of variance was found by the F test of Box, 81 the distribution-free Kruskal-Wallis statistic was used to test the null hypothesis of equality of genotype means.
Allele frequencies were estimated for the population by the gene-counting method. Average allele effects were estimated with the formula given by Sing and Davignon. 22 Fisher 82 introduced the average effect of an allele as the expected deviation from the population mean of an individual carrying that allele. It is a method for assigning a phenotypic effect to a haploid genotype, even when the phenotype is expressed only in diploid individuals. 83 There are as many average effects as there are alleles, and the sum of average effects weighted by their expected relative allele frequencies is zero.
We tested different hypotheses about average effects, depending on whether we treated the genes as two-allele or three-allele systems. When only two alleles were considered, we hypothesized no difference between the average effects of the two alleles, which is equivalent to the hypothesis that the average effect of each allele is zero. For three-allele systems such as is the case for apo E, a number of alternative hypotheses about average effects may be considered. We chose to contrast the average effects due to the less common alleles, e 2 and e 4 , with the average effect due to e 3 . The null hypotheses being tested are Thus, for each trait, we asked whether there was a significant difference between the phenotypic effects of the less common allele and the common e 3 allele, a biologically relevant hypothesis, by applying a twotailed test of significance.
Because the distributional properties of estimates of average effects are complex and not known, in this article we used a sampling/resampling approach 84 to test hypotheses about average effects. Repeated samples were generated from the observed sample of data by resampling without replacement and allocating the observations (adjusted values of dependent variables) at random to the genotype classes. For each sample, the contrasts of the estimates of average effects described above were computed. Repeated random sampling generates a sample-dependent distribution for each contrast that is used to estimate the probability of obtaining the value of the contrast computed from the observed sample. The proportion of contrasts that exceeds the value computed for the observed sample of data is taken to be the probability that the actual outcome arose by chance. If twice this probability was less than 0.05, we rejected the null hypothesis.
The large sample sizes involved in this study prohibited us from generating all possible permutations of the data. Thus, a random subset was obtained. The probability of observing the actual contrast in a random subset of permutations is subject to sampling variability, which is a function of the number of permutations and the true probability value. 83 Because the permutation testing used substantial computer resources, it was performed in two stages. We first performed 1,000 permutations of the data, for which a probability of 0.05 had a 99% confidence interval of 0.033-0.069. If the observed probability was between 0.01 and 0.10, the testing was redone with 15,000 permutations of the data to minimize the variability associated with a particular subset of random permutations. The 99% confidence interval for a probability estimate of 0.05 with 15,000 permutations is 0.0455-0.0547.
The contribution of differences among single-locus genotype means to the phenotypic variance of a trait was estimated by use of the unbiased statistic given by Boerwinkle and Sing. 85 The biased estimate of variance due to genotypic differences can be subdivided into the variance due to additive effects and the variance due to dominance. 22 Because there is no method for directly computing unbiased estimates of these two components of genetic variance, they were estimated by apportioning the unbiased estimate of genotypic variance according to the relative proportions obtained from the partitioning of the biased estimate of genotypic variance. There is no test of the statistical significance of these variance components. We took the test of equality of the genotype means as a measure of statistical significance of the genetic variance due to a particular polymorphism and used the sampling/resampling strategy described above as a measure of the significance of genetic variance attributable to additive allele effects. No corresponding test of the variance attributable to deviations due to dominance has been developed.
It is not possible to compare the average effects of an allele among the quantitative risk factor traits that have different units of measurement and different means and variances. Alternatively, we computed a standardized average effect of an allele by dividing the estimate of the average effect by the square root of the residual variance obtained from the one-way analysis of variance of genotypic effects on the trait.
We assume throughout the presentation given below that phenotypic differences among genotypes inferred from the isoforms of apos E, A-IV, and H are caused by allelic variations that code for amino acid substitutions in these proteins. We cannot rule out the possibility that such phenotypic differences are actually due to DNA changes that are closely linked to the DNA differences responsible for the amino acid changes. The exact nature of the DNA change that is responsible for a phenotypic effect is difficult to establish. In vitro studies reviewed by Davignon et al 16 and Mahley 18 argue that the amino acid differences that determine the apo E isoforms are responsible for functional differences in lipid metabolism that influence plasma levels of lipids and lipoproteins. Similar studies of apo A-IV and H have not been performed. (Table 1) The mean age of the 227 men was 43.8 years (range, 27-62 years), and the mean age of the 226 women was 41.7 years (range, 26-63 years). The mean height of the men was 177.6 cm and the mean weight was 85.2 kg, whereas the mean height of the women was 164.5 cm and mean weight was 69.0 kg. There were 45 (19.8%) men and 39 (17.3%) women who were current smokers. For the analyses presented here, persons who had never smoked and former smokers were grouped together. One woman had no data for RBC Na-Li CNT. Men had significantly higher mean levels of total cholesterol, triglycerides, apo B, apo C-II, apo C-III, apo E, RBC Na-Li CNT, and blood pressure, whereas women had significantly higher levels of HDL cholesterol and apo A-I. The variances of cholesterol, triglycerides, apo A-II, apo C-II, apo C-III, apo E, and RBC Na-Li CNT were significantly greater for men than for women, whereas women showed more variability in HDL cholesterol and blood pressure levels. Even after adjusting for age, age squared, weight, height, and smoking status, these gender differences in variances remained highly significant (/V<0.001). The greatest skewness was observed for triglycerides in men and women and for apo C-III and apo E in men. Gender-specific age distributions of the lipid and apolipoprotein traits have been given by Kottke et al. 86 
Results
Description of the Sample
Effects of Concomitants (Table 2)
The percentages of total sample sums of squares associated with independent concomitant variables included in selected regression models are given in Table 2 for men and women separately. A linear trend with the date of assay was significant for RBC Na-Li CNT and apo B in women and for apo A-I in men. In women additional effects of age were significant for total cholesterol, triglycerides, apo B, apo C-II, apo C-III, and blood pressure levels. No significant age effects were observed in men for any of the dependent variables. Adding height to the models had little effect in general but did explain a significant increase in the percentage of triglyceride and HSignificant at /V=0.051 level; #significant at /V=0.053 level.
apo E variability in women. Weight significantly increased the explanatory power of the regression in all variables except total cholesterol and apo E, with major effects for triglycerides, HDL, apo A-I, apo B, apo C-II, apo C-III, RBC Na-Li CNT, and blood pressure. Smoking was the last variable to be entered. A statistically significant increase in the regression sum of squares was observed for apo A-II and apo B in both genders. Overall, the concomitants accounted for a statistically significant percentage of the sample variability for all variables except cholesterol (4.7%), apo C-III (5.4%), and apo E (4.5%) in men. Concomitants explained the largest percentage of interindividual variability in women for apo B (24.0%) and triglycerides (22.5%) and in men for HDL cholesterol (20.0%). Overall, the percentage of variability explained by the complete regression model was quite similar for men and women for HDL cholesterol, apo A-I, apo A-II, and apo E, while very dissimilar explanations were observed for men and women for total cholesterol, triglycerides, blood pressure, apo B, apo C-II, and apo C-III.
Genotype Distributions and Allele Frequencies (Table 3)
The distributions of genotypes for the apo E, apo A-FV, and apo H polymorphisms are given in Table 3 .
For apo E, e 3/3 was the most common genotype and e 2/2 was the rarest. The distribution of genotypes was not significantly different between genders, and pooled frequencies were in Hardy-Weinberg equilibrium. The percentage of heterozygotes was 38.6%. The estimates of the relative frequencies of the apo E alleles were 0.0728 for e 2 , 0.777 for e 3 , and 0.150 for e,.
The 111 genotype was the most common apo A-IV genotype and together with the 2/1 genotype accounted for 98.9% of the sample. In the pooled sample the percentage of heterozygotes was 16.8%, and the estimates of the allele frequencies were 0.911 for A-IV*1, 0.085 for A-IV*2, and 0.003 for A-IV*3. Because all genotypes of this three-allele system were not represented and because average effects (see below) cannot be computed in this situation, we pooled the two less common alleles for subsequent analyses. The genotype frequencies of this two-allele system were not significantly different between genders, and the pooled frequencies were in HardyWeinberg equilibrium.
For apo H, the 2/2 genotype was most common, while no 1/1 homozygotes were observed. Estimates of the allele frequencies were 0.044 for apo H*l, 0.893 for apo H*2, and 0.063 for apo H*3, and the percentage of heterozygotes was 18.8%. Again, the 
Effect of Genotypes on Mean Levels (Table 4)
There was significant (/V<0.07) variability among apo E genotype means for total cholesterol, triglycerides, and apos B, C-II, and E in one or both genders (Table 4 ). Significant variability in total cholesterol, triglycerides, and apo B was observed among apo E genotype means in women but not in men. The rankings of genotype means were similar in both genders. Highest total cholesterol and triglyceride values were associated with the e 2/2 genotype class. The mean cholesterol was lower and the mean triglycerides higher for the e m genotype than for the e 3l3 genotype. The e 4/3 and e 4/4 means for cholesterol and triglycerides were higher than e 3/3 means. The e 3/2 genotype had lower apo B levels than did e 3/3 homozygotes, which were lower than those for the e 4l3 genotype. The effects of the apo E genotypes on plasma apo C-II and apo E levels were significant in both genders (Pr<0.07). For both apo C-II and E, e m had higher levels than did e 3/3> and the e 2/2 genotype had the highest levels. Apo E genotypes had the largest effects on plasma apo E levels. Men ranged from 2.7 mg/dl for the mean of the e 4l4 genotype to 20.3 mg/dl for the mean of the e m genotype. The range for women was 2.4 mg/dl for the e 4l4 genotype to 9.4 mg/dl for the e 2/2 genotype.
Results of the analyses of effects associated with genotypes of the apo A-IV locus are presented in Table 5 . Men and women were pooled for this analysis because there were no women in the x/x class of pooled genotypes. No statistically significant results were found for the lipids, apolipoproteins, and blood pressure variables. Except for RBC Na-Li CNT, analyses based on the three-allele (six-genotype) system either by gender or by combining genders gave essentially the same results as analyses based on the two-allele (three-genotype) system. In the three-allele analysis, the RBC Na-Li CNT differences among genotype means were highly significant (Pr=0.027), with data pooled across genders. For the two-allele analysis, mean RBC Na-Li CNT was 304.0 /imo\/\ cells/hr for the 1/1 genotype and 280.2 /imol/1 cells/hr for the 1/x genotype, a 23.8 /nmol/1 cells/hr difference (Pr=0.047). Table 6 presents the analysis of variation of adjusted variables among three apo H genotype classes determined by the H*2 and x alleles formed by pooling alleles H*l and H*3. Significant variability among genotypes was found for levels of plasma apo A-I in women and plasma apo E in men.
Estimates of Average Allele Effects (Table 7)
Two patterns of relation between the size of the average effects and the three apo E alleles were observed. For levels of total cholesterol, apo E, and apo B, the rare alleles were associated with opposite average effects in both genders. e 2 was associated with lower total cholesterol and apo B and higher apo E levels. In contrast, the e 4 allele was associated with higher levels of total cholesterol and apo B and lower apo E levels. Among men the average effect of e 2 was significantly different from the average effect of e 3 for apo E and apo B levels. Among women these contrasts were significant at the 0.08 level of probability. The difference between the average effect of the c, allele and the e 3 allele reached statistical significance only for apo E levels in women. HDL, high density lipoprotein; Apo, apolipoprotein; RBC Na-Li CNT, red blood cell sodium-lithium countertransport; SBP, systolic blood pressure; DBP, diastolic blood pressure.
•Indicates nonequality of variance among genotype classes (Pr<,0.05) and therefore, Kruskal-Wallis (K-W) test was used.
tOne missing value among women.
A second pattern of apo E allele effects was observed for triglycerides, HDL cholesterol, apo A-I, and apo A-II. For these traits the rare apo E alleles were found to be associated with similar deviations of the average effects. Both the e 2 and e 4 alleles were associated with increased levels of triglycerides and decreased levels of HDL cholesterol, apo A-I, and apo A-II in both genders. The average effects of the e 2 allele were significantly different from the average effects of the e 3 allele for triglycerides in both genders and for HDL cholesterol in men at the 0.10 level of probability. The average effect of the e 4 allele was significantly different from the average effect of the e 3 allele for HDL cholesterol in both genders and for triglycerides in women at the 0.10 level of probability.
For apo A-IV and apo H, average effects were computed for a two-allele, three-genotype system. The contrast of average effects of apo A-IV alleles was statistically significant for apo A-II at the 0.07 level of probability. The next largest apo A-IV effect was on RBC Na-Li CNT level. The A-W*l allele effect was 1.28 ^,mol/l cells/hr and for the combined effects of alleles A-IV*2 and A-IV*3 was -13.1 p,mol/l cells/hr. This difference was not statistically significant (Pr=0. 20) . Permutation testing of the contrast of the effect of the H*2 allele with the combined effect of the H*l and H*3 alleles suggests a possible influence on apo A-I and apo C-III in women only (0.05</V<0.10).
The separate analyses of each trait presented in Table 7 do not deal with the impact of a particular allele on a combination of traits. Although a multivariate test of a vector of average effects has not been developed, the graphical presentation of the standardized average allele effects given in Figures  1-5 reveals certain relations. Traits are ordered according to their primary involvement with triglyceride, total cholesterol, and HDL cholesterol metabolism. For all three loci, the common allele is generally associated with the smallest standardized effects. The profile of effects associated with each of the apo E alleles is quite similar in men and women (Figures 1 and 2) . The rarer alleles of apo E are associated with the largest phenotypic deviations from the apo E and apo B means. The e 2 allele is associated with increased levels of plasma apo E and triglycerides and decreased levels of plasma apo B and total cholesterol. The e, allele predicts elevated plasma apo B and total cholesterol, but the observed lower plasma apo E levels associated with this allele are not associated with lower triglycerides.
The combined effects of the two rarer apo A-IV alleles predict lower levels of every one of the measures of lipid metabolism (Figure 3 ). This observation differs markedly from the heterogeneity of the impact of rarer apo E alleles among the component traits of lipid metabolism (Figures 1 and 2) . In contrast to the systematic effects of the apo E and apo A-IV alleles, the effects of the apo H alleles on the profile of traits do not appear to represent a pattern of relations that is consistent between genders. Elevated HDL cholesterol and apo A-I in both men and women may be an exception (Figures 4 and 5) . M, men; W, women; HDL, high density lipoprotein; Apo, apolipoprotein; RBC Na-Li CNT, red blood cell sodium-lithium countertransport; SBP, systolic blood pressure; DBP, diastolic blood pressure.
'Indicates nonequality of variance by genotype class (/V<0.05) and therefore, Kruskal-Wallis (K-W) test was used. tOne missing value among women. (Table 8 ) Table 8 gives the estimates of the contribution of the structural allelic variations at each of the three loci to the phenotypic variance of each of the traits in the Rochester population, using data that have been adjusted for concomitants. The total genetic variance attributable to each locus was subdivided into variance due to additive (allelic) effects and variance of deviations due to dominance (nonallelic) effects.
Estimates of Population Variance
Apo E genotypic differences have the greatest impact on the phenotypic variance of total cholesterol, triglycerides, apo B, apo C-II, and apo E. The Permutation tests of significance of two contrasts of average effects described in text are given. Apo, apolipoprotein; HDL, high density lipoprotein; RBC Na-Li CNT, red blood cell sodium-lithium countertransport; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Apo E alleles in men 2
Apo E alleles in women contribution of genotypic variation for each trait is greatest in women. For men these estimates are 0.77%, 2.51%, 1.51%, 1.86%, and 10.64% of total cholesterol, triglycerides, apo B, apo C-II, and apo E, respectively. For women these estimates are 8.01%, 22.76%, 5.52%, 7.76%, and 15.76% of total cholesterol, triglycerides, apo B, apo C-II, and apo E, respectively.
Estimates of the contribution of apo A-IV to prediction of phenotypic variation did not exceed 1% for any of the traits considered (data not shown). The largest values were 0.44% for apo A-II levels and 0.75% for RBC Na-Li CNT levels. Estimates of genetic variance associated with the apo H locus were also quite small (data not shown). The largest values were 1.94% for apo A-I levels and 0.83% for apo C-III levels in women.
Exclusion of Hyperlipidemic Subjects
This study did not exclude individuals because of their lipid status, as this would have altered the population of inference. However, because earlier studies have often done so, we considered how exclusion of hyperlipidemic individuals would affect the impact of the apo E polymorphism on plasma levels of total cholesterol, triglycerides, and apo E. Such an analysis was done only for men because there were no e 2/2 women with normal cholesterol values. We excluded five men who had plasma total cholesterol values more than two standard deviations above the mean and then adjusted for the effect of concomitants (date of assay, age, age squared, height, weight, and smoking status) by linear regression. Mean plasma cholesterol levels did not vary significantly (iV=0.25) by apo E genotype. The proportion of total phenotypic variability due to genotype doubled to 1.6%, compared with 0.8% in the analysis of all subjects (Table 8) , and the residual phenotypic variance decreased by 36%, from 1,685 (Table 8) to 1,085. The average effects due to the e 2 allele and the e 4 allele were computed to be -13.1 and 3.1 mg/dl, respectively.
If hypertriglyceridemic individuals (triglycerides >400 mg/dl [n=7]) were excluded, the relation be- tween apo E genotype and apo E levels adjusted for concomitants became more pronounced, and apo E genotypic variation accounted for 18.5% of phenotypic variation, of which 91.4% (16.9%) was due to additive allele effects. The average effects due to the e 2 allele and the e, allele were 1.48 and -1.19 mg/dl, respectively. In this subsample there was no significant association between apo E genotype and mean adjusted triglyceride levels (Kruskal-Wallis test, /V=0.30), with average effects of 12.5 and 4.80 mg/dl due to the e 2 and €4 alleles, respectively. The proportion of phenotypic variation due to apo E genotypic variation was reduced by one half to 1.2% in this subsample, compared with 2.5% in men from the entire sample.
Discussion
Participants and nonparticipants in epidemiological studies of cardiovascular disease have been found to differ in health behavior, social characteristics, and mortality outcome. 8788 How individuals included in this study differ from those who chose not to participate has not been assessed. The sample of married and fecund unrelated adults used in the present analyses is expected to be more representative of the population at large than persons ascertained by a hospital-based registry. The low proportion of smokers (<20%) in the present sample is consistent with the finding that married persons have healthier lifestyles and may be at lower risk for death 87 -89 -91 than the general population. Because those invited to participate were selected without regard to health status, the only condition being that they have at least two school-age children in the Rochester, Minn., school system, we assume that they are representative of the distribution of genetic variations and quantitative risk factor levels for the major fraction of 26-to 60-year-olds in the Rochester population. The relative allele frequencies of the three genes studied are certainly very similar to those estimated for other Caucasian populations.
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-5561 After exclusion of those using medications that may have affected lipid levels and those taking antihypertensive medications, average lipid levels, blood pressure, and relative weight were very similar in the study subjects and in persons participating in the Lipid Research Clinics studies. 92 Because the etiology of the continuously distributed quantitative traits being studied involves many factors, each making a relatively small contribution to an individual's trait level, it is unlikely that a major difference for any cause of phenotypic variance exists between those included in the sample and those who were not sampled because they did not have children in the Rochester school system.
Inferences about the causes of phenotypic variation in the younger and older generations of the Rochester population cannot be made from this study. Even though the sample of reproducing parents may be considered as representative of the pool of allelic variations to be found in the grandparents and children of the population, the impact of such variation on the distribution of quantitative traits among individuals in younger or older persons may not be the same. Furthermore, the role of nongenetic sources of variation may differ across generations. Studies of the impact of the apo E, A-IV, and H polymorphisms and measures of concomitant traits in the younger and older generations of the Rochester population are in progress.
Major gender differences in the frequency distribution of intermediate risk factor traits and differences between men and women in the contribution of variation in concomitants and measured genotypes to the prediction of interindividual variation of these traits are obvious from our study. It is widely accepted that the average values of quantitative risk factor traits associated with CAD are different between men and women. However, gender differences in total phenotypic variance or in the causes of interindividual variation of these traits has not been widely appreciated. Despite the fact that the parental pairs studied share the same household environments and the same gene pool, as documented by the three genes considered, men and women of the Rochester population had very different estimates of the relative contribution of genetic and environmental factors to variation of particular traits. For measures of plasma cholesterol and triglyceride metabolism, the total phenotypic variance is larger and the relative contribution of measured concomitants and the three polymorphic genes is smaller in men than in women. These gender differences are not apparent for variation in plasma HDL cholesterol, apo A-I, or apo A-II. These findings unquestionably affirm the importance of considering men and women separately when studying the causes of phenotypic variation in the population at large. Biometric studies that adjust for gender differences before estimation of genetic and environmental sources of trait variation may be particularly susceptible to biased inferences about the relative role of genetic and environmental factors.
A proper study to unravel the nature of gender differences is a formidable challenge. Even if the environmental factors that are involved could be identified, precise measures of exposures are very difficult to obtain in free-living humans, and for those that can be measured, a study design for estimating and testing hypotheses about gender-by-genotype-byenvironment interaction effects in the human population at large may not be attainable. Randomly sampled pairs of identical twins exposed to candidate environmental factors offer a promising paradigm. Unfortunately, any sampling scheme that makes possible orthogonal estimates of effects of genotype, environment, and their interactions will not represent the relative frequencies and the range of environmental exposures that are found in the population at large. This is the first study of the contribution of multiple candidate loci to the genetic architecture of multiple intermediate quantitative traits that are measures of lipid metabolism and blood pressure regulation in a single population. All three candidate loci are polymorphic for three alleles but differ in the to quantitative trait variability is the greatest of the three genes studied here.
The relative impact of each of the three polymorphisms varies among the traits studied. Apo E had effects on the greatest number of traits, including those shown earlier for plasma levels of apo E, apo B, and cholesterol.
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" 100 The effect of apo E on triglycerides was dependent on the inclusion of hypertriglyceridemic subjects and has been found earlier in only two studies. 9698 The impact of the apo A-IV and H alleles on trait variation is obviously less than that of apo E. Earlier studies have also shown insignificant effects of allelic variation in A-IV on lipid traits. 5657 One suggestion of a significant influence on HDL variability 58 is consistent with an involvement in reverse cholesterol transport. 101 A possible role for apo H in HDL metabolism is supported by our study, by studies of the Nigerian population, 102 and by studies of persons with no detectable levels of apo H. 52 Effects of allelic variation in the apo E protein were greatest on the plasma levels of E and other apolipoproteins, while having lesser effects on levels of the lipids. This ordering is consistent with the hierarchical models of organization of gene effects that have been suggested. 103104 The proportion of variance of the adjusted plasma apo E levels due to allelic variation in apo E was less than 20% in both men and women. In men the greatest fraction of this genetic variation was attributable to the effects of dominance. These findings suggest a major role for interactions between alleles in the determination of the genetic architecture of plasma apo E levels and that a large fraction of phenotypic variation remains to be explained by other genetic and environmental factors.
During the past decade many genes have been identified that are candidates for making a contribution to explaining variation in the risk of CAD. 105 Nearly all research on the causes of interindividual differences in the risk of CAD focuses on the relation between allelic variation in these candidates and variation in the intermediate risk factor traits that are predictors of disease. There is a dearth of knowledge about the relative contribution of a particular allele to prediction of a particular clinical outcome. Using allelic variations to directly predict clinical manifestations that aggregate in families but that do not segregate in a Mendelian fashion presents a logical conundrum. There are many reasons for this state of affairs. Etiologic pathways of causation between variation in the genes involved in regulating lipid metabolism and the variation in risk for CAD obviously involve many quantitative intermediate traits. As our study emphasizes, interindividual variation in each of these traits may be influenced by many genes and exposure to many environmental factors. Hence, a simple Cartesian relation between gene variations and disease outcomes is an unrealistic expectation.
Is there a strategy for relating gene variation to variation in risk of CAD? We have argued 106 that to M, men; W, women; HDL, high density lipoprotein; Apo, apolipoprotein; RBC Na-Li CNT, red blood cell sodium-lithium countertransport; SBP, systolic blood pressure; DBP, diastolic blood pressure.
'Percentage of total variance. tNegative estimates of variance components were interpreted as estimates of zero, in which case the estimate of unexplained variance was taken to be the estimate of trait variance for the population at large. appropriately evaluate the utility of genetic variation in predicting variation in risk of CAD requires at least two steps. First, it is necessary to understand how genetic variation determines variation in intermediate quantitative traits that combine to determine an individual's risk of disease. Our study suggests that any particular polymorphic gene is expected to have only small effects on these intermediate traits. More than one gene will influence variation in a particular trait, and each gene may have pleiotropic effects on many traits. This finding is consistent with pioneering research of the genetic architecture of quantitative traits in maize, 107 which establishes that mapping of effects between genetic loci and quantitative traits is not one-to-one. Second, it is necessary to establish the network of causation between genotype and development of CAD through intermediate traits. 
